Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
WZ811
Cat. No.:
0225LY-1147
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
WZ811 is a novel small-molecule antagonist of CXCR4, characterized by an EC50 of 0.3 nM.
Synonym:
55778-02-4; WZ 811; N,N'-(1,4-phenylenebis(methylene))bis(pyridin-2-amine); N1,N4-Di-2-pyridinyl-1,4-benzenedimethanamine; WZ-811; N-[[4-[(pyridin-2-ylamino)methyl]phenyl]methyl]pyridin-2-amine; N,N'-(1,4-Phenylenebis(methylene))-bis(pyridin-2-amine); N-[(4-{[(Pyridin-2-yl)amino]methyl}phenyl)methyl]pyridin-2-amine; N,N'-(1,4-phenylenebis(methylene))dipyridin-2-amine
CAS No.:
55778-02-4
Compound CID:
11565518
Formula:
C18H18N4
Formula Weight:
290.36
Specification
Targets&IC50:
CXCR4: 0.3 nM(EC50)
Relative Density:
1.229 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
WZ811 can be used in oncology research to study the selective antagonism of the CXCR4 chemokine receptor.
Library Information
Target:
CXCR4
Receptor:
CXCR4
Pathways:
GPCR/G protein signaling; Autophagy; Immunology/Inflammation
Plate Number:
AOCL-15
Plate Location:
g3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
28 mg/mL; 96.43 mM
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
